TY - JOUR
T1 - A randomized pilot study of nitrate supplementation with beetroot juice in acute respiratory failure
AU - Files, D. Clark
AU - Heinrich, Timothy
AU - Shields, Katherine L.
AU - Love, Nathan J.
AU - Brailer, Carly
AU - Bakhru, Rita N.
AU - Purcell, Lina
AU - Flores, Lori
AU - Gibbs, Kevin
AU - Miller, Gary D.
AU - Morris, Peter E.
AU - Berry, Michael J.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Nitrate rich beetroot juice (BRJ) can enhance nitric oxide signaling, leading to improved physical function in healthy and diseased populations, but its safety and biologic efficacy have not been evaluated in a critically ill population. We randomized 22 previously functional acute respiratory failure patients to either BRJ or placebo daily until day 14 or discharge. We measured blood nitrate and nitrite levels and quantified strength and physical function at intensive care unit (ICU) and hospital discharge. Participants were predominantly male (54%), aged 68.5 years with an APACHE III score of 62. BRJ increased plasma nitrate (mean 219.2 μM increase, p = 0.002) and nitrite levels (mean 0.144 μM increase, p = 0.02). We identified no adverse events. The unadjusted and adjusted effect sizes of the intervention on the short physical performance battery were small (d = 0.12 and d = 0.17, respectively). In this pilot trial, administration of BRJ was feasible and safe, increased blood nitrate and nitrate levels, but had a small effect on physical function. Future studies could evaluate the clinical efficacy of BRJ as a therapy to improve physical function in survivors of critical illness.
AB - Nitrate rich beetroot juice (BRJ) can enhance nitric oxide signaling, leading to improved physical function in healthy and diseased populations, but its safety and biologic efficacy have not been evaluated in a critically ill population. We randomized 22 previously functional acute respiratory failure patients to either BRJ or placebo daily until day 14 or discharge. We measured blood nitrate and nitrite levels and quantified strength and physical function at intensive care unit (ICU) and hospital discharge. Participants were predominantly male (54%), aged 68.5 years with an APACHE III score of 62. BRJ increased plasma nitrate (mean 219.2 μM increase, p = 0.002) and nitrite levels (mean 0.144 μM increase, p = 0.02). We identified no adverse events. The unadjusted and adjusted effect sizes of the intervention on the short physical performance battery were small (d = 0.12 and d = 0.17, respectively). In this pilot trial, administration of BRJ was feasible and safe, increased blood nitrate and nitrate levels, but had a small effect on physical function. Future studies could evaluate the clinical efficacy of BRJ as a therapy to improve physical function in survivors of critical illness.
KW - Critical illness
KW - Intensive care unit acquired weakness
KW - Muscle wasting
KW - Nitric oxide
KW - Physical function
UR - http://www.scopus.com/inward/record.url?scp=85074355201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074355201&partnerID=8YFLogxK
U2 - 10.1016/j.niox.2019.10.009
DO - 10.1016/j.niox.2019.10.009
M3 - Article
C2 - 31669503
AN - SCOPUS:85074355201
SN - 1089-8603
VL - 94
SP - 63
EP - 68
JO - Nitric Oxide - Biology and Chemistry
JF - Nitric Oxide - Biology and Chemistry
ER -